These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10687144)

  • 1. Vitamin D3 treatment to diminish the levels of immune suppressive CD34+ cells increases the effectiveness of adoptive immunotherapy.
    Wiers KM; Lathers DM; Wright MA; Young MR
    J Immunother; 2000 Jan; 23(1):115-24. PubMed ID: 10687144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure of tumor-reactive lymph node cells to kill tumor in the presence of immune-suppressive CD34+ cells can be overcome with vitamin D3 treatment to diminish CD34+ cell levels.
    Wiers K; Wright MA; Vellody K; Young MR
    Clin Exp Metastasis; 1998 Apr; 16(3):275-82. PubMed ID: 9568645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulation of immune suppressive CD34+ cells from normal bone marrow by Lewis lung carcinoma tumors.
    Wright MA; Wiers K; Vellody K; Djordjevic D; Young MR
    Cancer Immunol Immunother; 1998 Jul; 46(5):253-60. PubMed ID: 9690453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune modulation by interleukin-12 in tumor-bearing mice receiving vitamin D3 treatments to block induction of immunosuppressive granulocyte/macrophage progenitor cells.
    Prechel MM; Lozano Y; Wright MA; Ihm J; Young MR
    Cancer Immunol Immunother; 1996 May; 42(4):213-20. PubMed ID: 8665568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
    Pak AS; Ip G; Wright MA; Young MR
    Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence.
    Young MR; Ihm J; Lozano Y; Wright MA; Prechel MM
    Cancer Immunol Immunother; 1995 Jul; 41(1):37-45. PubMed ID: 7641218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy with dendritic cells pulsed with tumor-derived gp96 against murine lung cancer is effective through immune response of CD8+ cytotoxic T lymphocytes and natural killer cells.
    Shinagawa N; Yamazaki K; Tamura Y; Imai A; Kikuchi E; Yokouchi H; Hommura F; Oizumi S; Nishimura M
    Cancer Immunol Immunother; 2008 Feb; 57(2):165-74. PubMed ID: 17628800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: gamma interferon plus tumor necrosis factor alpha synergistically reduces immune suppressor and tumor growth-promoting activities of bone marrow cells and diminishes tumor recurrence and metastasis.
    Young MR; Wright MA
    Cancer Res; 1992 Nov; 52(22):6335-40. PubMed ID: 1423279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.
    Machlenkin A; Goldberger O; Tirosh B; Paz A; Volovitz I; Bar-Haim E; Lee SH; Vadai E; Tzehoval E; Eisenbach L
    Clin Cancer Res; 2005 Jul; 11(13):4955-61. PubMed ID: 16000595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of aging on immune modulation by tumor.
    Young MR; Kolesiak K; Achille NJ; Meisinger J; Gonzalez E; Liu SW; Wrone-Smith T; Lathers DM
    Cancer Immunol Immunother; 2001 Aug; 50(6):315-20. PubMed ID: 11570585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
    Merritt RE; Yamada RE; Crystal RG; Korst RJ
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways.
    Sawant A; Schafer CC; Jin TH; Zmijewski J; Tse HM; Roth J; Sun Z; Siegal GP; Thannickal VJ; Grant SC; Ponnazhagan S; Deshane JS
    Cancer Res; 2013 Nov; 73(22):6609-20. PubMed ID: 24085788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ineffective immune enhancement by IL-12 in tumor-bearing mice whose immune depression is mediated by suppressive granulocyte-macrophage progenitor cells.
    Prechel MM; Lozano Y; Wright MA; Ihm J; Young MR
    Cancer Lett; 1995 Jun; 92(2):235-42. PubMed ID: 7600536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superiority of interleukin-12-transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice.
    Sumimoto H; Tani K; Nakazaki Y; Tanabe T; Hibino H; Wu MS; Izawa K; Hamada H; Asano S
    Cancer Gene Ther; 1998; 5(1):29-37. PubMed ID: 9476964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
    Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
    J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.
    Wang LX; Shu S; Disis ML; Plautz GE
    Blood; 2007 Jun; 109(11):4865-76. PubMed ID: 17284532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of spontaneous metastatic lung cancer with tumor antigen-pulsed, interleukin-18 gene-modified dendritic cells].
    Chen J; Cao X; Xiu Q
    Zhonghua Yi Xue Za Zhi; 2001 Jul; 81(13):779-82. PubMed ID: 11798964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo.
    Yi KH; Nechushtan H; Bowers WJ; Walker GR; Zhang Y; Pham DG; Podack ER; Federoff HJ; Tolba KA; Rosenblatt JD
    Cancer Res; 2007 Oct; 67(20):10027-37. PubMed ID: 17942937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D3 treatment of tumor bearers can stimulate immune competence and reduce tumor growth when treatment coincides with a heightened presence of natural suppressor cells.
    Young MR; Lozano Y; Ihm J; Wright MA; Prechel MM
    Cancer Lett; 1996 Jul; 104(2):153-61. PubMed ID: 8665483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.